Sensei Biotherapeutics Files Pro Forma Financials for Massive Preferred Stock Conversion

summarizeSummary

Sensei Biotherapeutics filed a proxy supplement with pro forma financials showing the massive dilution from its upcoming Series B Preferred Stock conversion, which will increase common shares by over 1800%.

check_boxKey Events

• Pro Forma Financials for Preferred Stock Conversion

  The filing provides unaudited pro forma financial statements for Q1 2026, adjusted to reflect the conversion of Series B Preferred Stock into common stock.

• Massive Dilution Expected

  The conversion will result in the issuance of approximately 24,434,920 new common shares, increasing the total weighted-average shares outstanding by over 1800% from 1,295,052 to 25,729,972.

• Linked to Prior Financing and Acquisition

  The Series B Preferred Stock originated from a $200 million private placement and the acquisition of Faeth Therapeutics, both announced in February 2026.

• Shareholder Vote Scheduled

  The conversion is contingent on shareholder approval of 'Required Company Stockholder Matters' at the Annual Meeting scheduled for June 10, 2026.

auto_awesomeAnalysis

This DEFA14A filing provides crucial pro forma financial information detailing the impact of the upcoming conversion of Series B Preferred Stock into common stock. This conversion, contingent on shareholder approval on June 10, 2026, will result in the issuance of approximately 24.4 million new common shares, representing an over 1800% increase in outstanding shares. While highly dilutive for existing shareholders, this conversion is a necessary step to finalize the recapitalization and $200 million financing announced in March, which is critical for the company's operations given its recent 'going concern' warning.